Skip to content

US · ENLV · BIOTECHNOLOGY

Enlivex Therapeutics Ltd. (ENLV) intrinsic value and stock valuation

$1.05as of 2026-11-21 · Mkt cap 35.01M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Enlivex Therapeutics Ltd. DCF and intrinsic value

InvestorsCraft values ENLV with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ENLV’s statements →

Enlivex Therapeutics Ltd. Graham Number

Graham Number: $2,407.49d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Ness Ziona, TA 7403618 enlivex.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
$1.24B
20122025
Free cash flow
-$-10.48M
20122025
Total equity
$1.93B+122.5% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-15M-$-15.54M-$-29.39M-$-25.8M-$-19.29M
Net income$1.24B-$-15.01M-$-29.07M-$-31.06M-$-14.47M
EPSd$382.5M-$-10.96M-$-23.44M-$-25.25M-$-12.16M
Operating cash flow-$-10.42M-$-13.01M-$-23.52M-$-23.95M-$-17.54M
Capital expenditure-$-70K-$-100K-$-240K-$-8.12M-$-1.62M
Free cash flow-$-10.48M-$-13.11M-$-23.76M-$-32.08M-$-19.17M
Total assets$2.33B$27.7M$36.8M$67.6M$95.2M
Total debt$640K$530K$1.03M$4.85M$6.01M
Net debt-$-1.37M-$-2.77M$220K-$-45.1M-$-5.2M
Total equity$1.93B$23.6M$30.1M$56.8M$85M
Cash and short-term investments$5.87M$23.6M$27.3M$50.2M$84.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$330K$550K$830K$780K$550K
Gross profit-$-330K-$-550K-$-830K-$-780K-$-550K
Research and development expenses$8.92M$10.1M$19.2M$18.7M$12.9M
Selling, general and administrative expenses$5.68M$4.91M$6.14M$6.7M$6.24M
Other expenses$60K-$-50K$4.02M$400K$170K
Operating expenses$14.7M$15M$29.4M$25.8M$19.3M
Cost and expenses$15M$15.5M$29.4M$25.8M$19.3M
Interest income$790K$1.07M$1.56M$830K$120K
Interest expense$10K$10K$10K$5.26M$330K
Depreciation and amortization$330K$550K$830K$780K$550K
Ebitda-$-14.67M-$-14.47M-$-28.22M-$-25.02M-$-18.74M
Operating income-$-15M-$-15.54M-$-29.39M-$-25.8M-$-19.29M
Total other income/expenses, net$1.63B$520K$330K-$-5.26M$4.82M
Income before tax$1.62B-$-15.01M-$-29.07M-$-31.06M-$-14.47M
Income tax expense$382.7M$0.00$0.00$0.00$0.00
Net income$1.24B-$-15.01M-$-29.07M-$-31.06M-$-14.47M
Weighted average shares outstanding$3.05M$1.37M$1.24M$1.23M$1.19M
Weighted average diluted shares outstanding$3.23M$1.37M$1.24M$1.23M$1.19M
Balance sheet
20252024202320222021
Cash and short-term investments$5.87M$23.6M$27.3M$50.2M$84.1M
Net receivables$230K$1.3M$230K$650K$1.09M
Inventory$0.00$0.00$0.00$1.18M$0.00
Total current assets$1.74B$26M$33.8M$52.3M$86.4M
Property, plant and equipment, net$940K$1.15M$2.58M$14.9M$8.22M
Goodwill and intangible assets$582.5M$0.00$0.00$0.00$0.00
Long-term investments$370K$530K$310K$0.00$0.00
Total non-current assets$583.8M$1.69M$3.07M$15.3M$8.7M
Total assets$2.33B$27.7M$36.8M$67.6M$95.2M
Accounts payable$3.81M$810K$830K$1.95M$880K
Short-term debt$260K$230K$350K$650K$620K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9.02M$3.8M$6.06M$6.61M$4.72M
Long-term debt$380K$300K$690K$4.19M$5.39M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$383M$300K$690K$4.19M$5.39M
Capital lease obligations$640K$530K$1.03M$4.19M$6.01M
Total liabilities$392.1M$4.1M$6.75M$10.8M$10.1M
Common stock$28.7M$2.69M$2.14M$2.12M$2.11M
Retained earnings$1.11B-$-127.11M-$-112.09M-$-83.03M-$-51.97M
Accumulated other comprehensive income (loss)$1.1M$1.1M$1.1M$1.1M$1.1M
Total equity$1.93B$23.6M$30.1M$56.8M$85M
Total investments$4.24M$20.7M$26.8M$300K$72.9M
Total debt$640K$530K$1.03M$4.85M$6.01M
Net debt-$-1.37M-$-2.77M$220K-$-45.1M-$-5.2M
Cash flow statement
20252024202320222021
Net income$1.24B-$-15.01M-$-29.07M-$-31.06M-$-14.47M
Depreciation and amortization$330K$550K$830K$780K$550K
Stock-based compensation$1.78M$2.06M$1.95M$2.71M$2.91M
Change in working capital$810K-$-1.22M-$-1.82M$800K-$-1.36M
Accounts receivable-$-3.05M$430K$610K$280K-$-1.25M
Inventory$0.00$0.00$0.00-$-280K$1.25M
Accounts payable$3M-$-20K-$-1.12M$1.17M$440K
Net cash provided by operating activities-$-10.42M-$-13.01M-$-23.52M-$-23.95M-$-17.54M
Investments in property, plant and equipment-$-19.57M-$-100K-$-240K-$-8.12M-$-1.62M
Acquisitions, net$1.38M$0.00$0.00-$-9.71M-$-20.03M
Net cash used for investing activities-$-1.32M$9.06M-$-25.97M$62.5M-$-38.41M
Common stock issued$10.4M$6.45M$360K$150K$53.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.4M$6.45M$360K$150K$61M
Net change in cash-$-1.41M$2.5M-$-49.13M$38.7M$4.62M
Cash at end of period$2.01M$3.73M$1.23M$50.4M$11.6M
Operating cash flow-$-10.42M-$-13.01M-$-23.52M-$-23.95M-$-17.54M
Capital expenditure-$-70K-$-100K-$-240K-$-8.12M-$-1.62M
Free cash flow-$-10.48M-$-13.11M-$-23.76M-$-32.08M-$-19.17M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Enlivex Therapeutics Ltd.

        Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.

        CEO
        Oren Hershkovitz
        Employees
        34
        Beta
        1.52

        Explore

        Frequently asked questions

        What is the intrinsic value of Enlivex Therapeutics Ltd. (ENLV)?

        InvestorsCraft does not currently publish an intrinsic value for ENLV. How the IC value is calculated.

        Is ENLV undervalued?

        InvestorsCraft does not publish an undervaluation signal for ENLV at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.